FDA Approves Bemotrizinol: First New Sunscreen Ingredient in 25 Years

The United States Food and Drug Administration approved bemotrizinol as a new sunscreen active ingredient on June 9, 2026, ending a more than 25-year drought in new sun protection options for American consumers. The compound — also known by the brand names Tinosorb S and PARSOL Shield — has been widely used in European, Australian and Asian sunscreens since the year 2000 and is now cleared for use in US products.

What Makes Bemotrizinol Different?

Unlike older mineral-based sunscreen filters such as zinc oxide and titanium dioxide, bemotrizinol is a synthetic, oil-soluble UV filter that absorbs rather than reflects ultraviolet light. It is notable for its broad-spectrum coverage, blocking both UVA radiation — which causes skin aging and contributes to cancer risk — and UVB radiation, which causes sunburn.

One practical advantage over mineral sunscreens is that bemotrizinol does not leave the chalky white residue associated with zinc oxide-based products, making it easier to apply and less visible on darker skin tones.

Who Can Use It and How Much?

The FDA approved bemotrizinol for use by adults and children aged six months and older. Manufacturers are permitted to include it in sunscreen formulations at concentrations of up to 6 percent. Products containing the new ingredient are expected to reach US store shelves from August 9, 2026 onward — when the new marketing authorization takes effect.

Why Did It Take So Long?

Sunscreen ingredients in the United States face a uniquely demanding regulatory pathway compared to most countries. Under US law, sunscreen filters are classified as over-the-counter drugs rather than cosmetic ingredients, requiring safety and efficacy data that mirrors the pharmaceutical approval process. Several other UV filters already commonplace in European and Asian sunscreens have been awaiting FDA clearance for years. The approval of bemotrizinol marks the first time the FDA has expanded the list of allowed sunscreen actives since 2002.

Dermatologists and public health advocates welcomed the approval, noting that broader filter options give formulators more tools to create cosmetically elegant products that consumers will actually use. Daily UV protection remains one of the most evidence-backed interventions for reducing skin cancer risk over a lifetime.